Gene-modified Cell Treatments Market Size, Share, and Industry Analysis, By Therapy Type (Chimeric Antigen Receptor T-cell therapy, T-cell Receptor T-cell Therapies, Chimeric Antigen Receptor-Natural Killer Cell Therapy, and Others), By Disease Indication (Oncology, Hematology, Autoimmune Disorders, Rare Diseases, and Others), By End User (Hospitals & Specialty Clinics, Academic & Research Institutes, and Biotechnology & Pharmaceutical Companies), and Regional Forecast, 2026-2034

The global cell-based gene-edited therapy market is anticipated to grow substantially with an upward growth trajectory in the forecast period. The market growth is driven by advancements in gene editing tools such as CRISPR, TALENs, and base editors, enabling safer and more efficient modification of cells. The rising prevalence of hematologic malignancies, rare genetic disorders, autoimmune diseases, and cancer has created significant unmet needs, fuelling demand for durable, potentially curative treatments. Supportive regulatory frameworks such as the U.S. FDA’s RMAT and EMA’s PRIME designations, along with increased investment and strategic acquisition from large pharmaceutical companies, are projected to assist the market growth.

• For instance, in August 2025, Kite, a Gilead Company, acquired Interius BioTherapeutics, developing in vivo CAR therapeutics, for USD 350.0 million. This acquisition complemented the company’s expertise in cell therapy. This approach enables the generation of CAR T-cells directly within the patient’s body, offering a more durable and long-lasting therapeutic effect.

Furthermore, strategic collaborations, mergers, and acquisitions of key companies operating in the market to offer new and more advanced therapies and expand product offerings are anticipated to drive the growth of the market in the upcoming years.

Gene-modified Cell Treatments Market Driver

Advances in Precision Medicine Tools to Lead Rapid Pipeline Development and Drive Market Growth 

The advancement in precise editing tools such as CRISPR-Cas9, base editors, and TALENs has enabled safer and efficient genetic modifications of patient or donor-derived cells. These innovations facilitate multiplex editing, improved persistence, and resistance to tumor evasion mechanisms, which broaden the scope of treatable indications beyond hematological cancers into solid tumors, autoimmune diseases, and rare genetic disorders. Due to these factors, many key players are streamlining their resources toward pipeline development, leading to the growth of the market.

• In December 2023, Vertex Pharmaceuticals Incorporated received approval from the U.S. FDA for Casgevy as the first CRISPR-Cas9 edited cell therapy for sickle cell disease and β-thalassemia, showcasing regulatory acceptance of gene-edited cell products.
• Similarly, as of December 2024, 106 cell therapy products have been approved globally. Among which 13 are genetically modified cell therapies and 73 non–genetically modified cell therapies. 

Average Funding for National Genomic Program by key Organizations (in millions)

Gene-modified Cell Treatments Market Restraint

High Prices Along with Reimbursement Challenges to Hamper Adoption of These Novel Therapies, Retracting Growth

Reimbursement remains one of the biggest bottlenecks for cell-based gene therapies due to their extremely high upfront costs (often USD 0.5–2 million per treatment) and the uncertainty around the long-term durability of response. Health systems and payers face budget impact challenges, as a one-time curative therapy may exceed the annual drug budget for rare diseases. Additionally, the lack of standardized reimbursement models—such as outcomes-based or annuity payments—creates friction between manufacturers and payers, delaying patient access. This financial complexity often results in slow adoption outside of markets with strong risk-sharing frameworks (e.g., the U.S., Germany), restraining the global market’s growth potential. 

• For instance, in April 2021, Bluebird Bio Inc. withdrew Zynteglo (betibeglogene autotemcel) for transfusion-dependent β-thalassemia (TDT) from the German market after reimbursement negotiations failed. Such factors limit adoption and hamper market growth.

Gene-modified Cell Treatments Market Opportunity

Development of Scalability and Production Capacity to Meet Patient Demand Offers Lucrative Market Growth Opportunity 

Scalable manufacturing is a key factor to facilitate market growth and provide access to these gene-edited cell therapies to many patients. Automated, standardized platforms reduce variability, human error, and cost. They also enable multi-site production under consistent GMP standards, reducing lead times, improving yield, and facilitating regulatory compliance. This, in turn, allows companies to scale clinical trials faster and better plan commercial supply and support the increasing demand, creating new growth avenues.

• For instance, in August 2025, ElevateBio received comprehensive certification from the Initiative for Certification of Manufacturing Capabilities program for its viral gene delivery, non-viral gene delivery, and cell therapy manufacturing capabilities at its flagship ElevateBio BaseCamp facility in Waltham, Massachusetts. Such factors offer new growth avenues to the global market of gene-modified cell therapies.

Key Insights

The report covers the following key insights:

• Development of Gene-Modified Cell Therapy for New Disease Indications
• Regulatory Scenarios, By Key Countries/Regions
• Technological Advancements in the Gene-Modified Cell Therapy Market
• New Product Launches, By Key Players
• Pipeline Analysis, By Key Companies
• Key Industry Developments (Mergers, Acquisitions, Partnerships, Launches, etc.)
• Pricing & Reimbursement Landscape in the Gene-Modified Cell Therapy Market
• Manufacturing & Supply Chain Insights
• Investment & Funding Trends in the Market

Segmentation

Analysis by Therapy Type

On the basis of therapy type, the global gene-modified cell treatments market is segmented into chimeric antigen receptor T-cell therapy, T-cell receptor T-cell therapies, chimeric antigen receptor-natural killer cell therapy, and others. Among these, Chimeric Antigen Receptor T-cell therapy is expected to hold a leading market share. The high segmental share of these therapies is due to their efficiency in hematologic cancers and other rare conditions. Also, the broad commercial presence of products such as Kymriah, Yescarta, Abecma, and Breyanzi has established a clear market foothold and infrastructure. 

• For Instance, in July 2025, Autolus Therapeutics plc received marketing authorization from the European Commission (EC) for AUCATZYL for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

Analysis by Disease Indication

On the basis of disease indication, the market is segmented into oncology, hematology, autoimmune disorders,rare diseases, and others. 

Among these, the oncology segment is expected to generate a significant revenue share in the global gene-modified cell treatments market. These genes modified cell therapies support the urgent unmet medical need, driving rapid adoption of innovative therapies. Also, these therapies have showcased efficacy in hematologic malignancies, overcoming the limitations of traditional therapies. Moreover, the rapid expansion of pipeline candidates, approvals from regulatory bodies, and increasing investment in oncology targeted therapies to driving the growth in the segment. 

• For instance, in August 2024, Adaptimmune Therapeutics plc received the U.S. FDA approval of TECELRA for the treatment of adults with unresectable or metastatic synovial sarcoma who have received prior chemotherapy.

Analysis by End User

By end user, the market is divided into hospitals & specialty clinics, academic & research institutes, and biotechnology & pharmaceutical companies.

Hospitals & specialty clinics are expected to hold a significant share in the global gene-modified cell treatments market. Hospitals and specialty clinics play a central role in the gene-modified cell therapy market. They are the only settings equipped with the infrastructure for complex procedures and are often the epicenter of clinical trials. They offer specialized supervision along with supporting complex administration requirements. As a result, hospitals and specialty clinics dominate the treatment landscape and account for the largest market share due to their ability to deliver these advanced, high-touch therapies safely and effectively.

• For instance, in August 2025, Abeona Therapeutics collaborated with Ann & Robert H. Lurie Children’s Hospital of Chicago. The hospital is the first qualified treatment center in the U.S. to offer Zevaskyn, a cell-based gene therapy designed to treat wounds in patients with recessive dystrophic epidermolysis bullosa (RDEB).

Regional Analysis

By region, the market is divided into North America, Europe, Asia Pacific, the Middle East & Africa, and Latin America.

Request for Customization   to gain extensive market insights.

North America accounted for the largest share of the global gene-modified cell treatments market in 2024. The dominance of the region is due high prevalence of cancer and rare genetic diseases that drive demand for advanced therapies. It is a hub for research and development, along with numerous funding activities enabling rapid innovation and clinical trial activity. Furthermore, reimbursement structures in the region are increasingly adapting to cover novel gene-edited cell therapies, reducing barriers for patient access. These advantages reinforce the high market share of the region and propel growth.

• For instance, in September 2024, the Association for the Advancement of Blood & Biotherapies (AABB) extended its support for the proposed changes to chimeric antigen receptor (CAR) T-cell therapy and therapeutic apheresis coverage under the Centers for Medicare and Medicaid Services (CMS) physician fee schedule and Medicare Part B payment and coverage policies for the year 2025.

Europe is expected to grow with a significant market share in the forecasted period. The regional growth of the gene-modified cell treatments is attributed to the strategic collaboration of the established players to enhance their production capacities and expand product offerings. The region experiences strong government support and investment in cell and gene therapy infrastructure. There are high public health expenditure well well-established healthcare systems, and high clinical trial density, offering more pipeline progression. 

• For instance, in August 2025, Anocca AB raised USD 41.6 million to progress VIDAR-1, the company’s gene-edited TCR-T cell therapies targeting mutant KRAS in pancreatic cancer.

Asia Pacific is expected to grow at the highest CAGR during the forecast period. The region's growth can be attributed to rising biotech R&D investment, increasing government support, and favorable regulatory frameworks to encourage innovation. Also, there is a growing market demand due to increased awareness of precision medicinal therapies and a growing number of biotech startups.

• For instance, in April 2024, the Indian Institute of Technology, Bombay, and the Tata Memorial Hospital, in association with industry partner ImmunoACT, collaborated to develop NexCAR19 CAR-T therapy. This affordable cell therapy is indigenously developed for the treatment of blood cancers.

Key Players Covered

The global gene-modified cell treatments market is consolidated, with a few players capturing a major market player. The report includes the profiles of the following key players.

• Gilead Sciences (U.S.)
• Bluebird Bio, Inc. (U.S.)
• CRISPR Therapeutics AG (Switzerland)
• Novartis AG (Switzerland)
• Allogene Therapeutics, Inc. (U.S.)
• Sangamo Therapeutics, Inc. (U.S.)

Key Industry Developments

• In September 2024, Evotec SE collaborated with Novo Nordisk A/s to develop off-the-shelf cell therapy products. Under the collaboration, Novo Nordisk provided funding for technology development activities at Evotec’s R&D site in Germany.
• In January 2024, AbbVie Inc. collaborated with Umoja Biopharma to develop multiple in-situ generated CAR-T cell therapy candidates in oncology using the company's VivoVecTM platform.